Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 7
2007 17
2008 24
2009 28
2010 49
2011 131
2012 228
2013 308
2014 399
2015 294
2016 127
2017 65
2018 26
2019 18
2020 17
2021 28
2022 18
2023 10
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

1,575 results

Results by year

Filters applied: . Clear all
Page 1
[Telaprevir resistance].
Poveda E, García F. Poveda E, et al. Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Enferm Infecc Microbiol Clin. 2013. PMID: 24063900 Review. Spanish.
Telaprevir is an extremely potent antiviral drug. However, as with other direct-acting antiviral agents against the hepatitis C virus (HCV), this potency can be compromised by the rapid emergence of resistance mutations. ...The presence of polymorphisms or mutations associ …
Telaprevir is an extremely potent antiviral drug. However, as with other direct-acting antiviral agents against the hepatitis C virus …
Telaprevir.
[No authors listed] [No authors listed] Drugs R D. 2010;10(3):179-202. doi: 10.2165/11586020-000000000-00000. Drugs R D. 2010. PMID: 20945948 Free PMC article. Review.
Telaprevir (LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. ...As the first ever HCV protease inhibitor in phase III development, it is being studied in trial …
Telaprevir (LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the …
Telaprevir user's guide.
Liapakis AM, Jacobson I. Liapakis AM, et al. Liver Int. 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. Liver Int. 2012. PMID: 22212567 Review.
Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a regimen of telaprevir combined with pegylated interferon alfa and ribavirin (PR) over PR alone in patients with HCV genotype 1. ...Stopp …
Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a reg …
Telaprevir-related dermatitis.
Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Roujeau JC, et al. JAMA Dermatol. 2013 Feb;149(2):152-8. doi: 10.1001/jamadermatol.2013.938. JAMA Dermatol. 2013. PMID: 23560295 Clinical Trial.
Three cases of Stevens-Johnson Syndrome (SJS), and 11 cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were suspected, with 2 SJS and 3 DRESS cases considered likely. CONCLUSIONS: Telaprevir-related dermatitis occurs in a majority of telaprevir …
Three cases of Stevens-Johnson Syndrome (SJS), and 11 cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were suspected, …
Telaprevir user's guide.
Liapakis A, Jacobson I. Liapakis A, et al. Clin Liver Dis. 2011 Aug;15(3):555-71. doi: 10.1016/j.cld.2011.05.013. Clin Liver Dis. 2011. PMID: 21867936 Review.
This article discusses phase I, II, and III trials examining telaprevir's role in treating patients with HCV. We have now entered an era of combination therapy utilizing direct acting anti-virals, the start of which was marked by the FDA approval of HCV protease inhibitors …
This article discusses phase I, II, and III trials examining telaprevir's role in treating patients with HCV. We have now entered an …
Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.
Kiang TK, Wilby KJ, Ensom MH. Kiang TK, et al. Clin Pharmacokinet. 2013 Jul;52(7):487-510. doi: 10.1007/s40262-013-0053-x. Clin Pharmacokinet. 2013. PMID: 23553423 Review.
This article provides an unbiased review of the pharmacokinetic, pharmacodynamic, and drug-drug interaction data of telaprevir, an NS3/4A protease inhibitor. Telaprevir is well absorbed with fatty food, moderately protein bound (59-76 %) with a large volume of distr …
This article provides an unbiased review of the pharmacokinetic, pharmacodynamic, and drug-drug interaction data of telaprevir, an NS …
Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis.
Frost J, Rudy MJ, Leser JS, Tan H, Hu Y, Wang J, Clarke P, Tyler KL. Frost J, et al. J Virol. 2023 May 31;97(5):e0015623. doi: 10.1128/jvi.00156-23. Epub 2023 May 8. J Virol. 2023. PMID: 37154751 Free PMC article.
The effects of telaprevir were not seen when the treatment was delayed, and toxicity limited doses beyond 35 mg/kg. ...Telaprevir also protected motor neurons and improved paralysis outcomes in limbs beyond the site of viral inoculation. ...
The effects of telaprevir were not seen when the treatment was delayed, and toxicity limited doses beyond 35 mg/kg. ...Telaprevir …
Telaprevir Improves Memory and Cognition in Mice Suffering Ischemic Stroke via Targeting MALT1-Mediated Calcium Overload and Necroptosis.
Zhang YY, Peng JJ, Chen D, Liu HQ, Yao BF, Peng J, Luo XJ. Zhang YY, et al. ACS Chem Neurosci. 2023 Sep 6;14(17):3113-3124. doi: 10.1021/acschemneuro.3c00250. Epub 2023 Aug 9. ACS Chem Neurosci. 2023. PMID: 37559405
Moreover, telaprevir was able to inhibit the levels of necroptosis-associated proteins. ...Thus, telaprevir might have a novel indication for treating patients with ischemic stroke....
Moreover, telaprevir was able to inhibit the levels of necroptosis-associated proteins. ...Thus, telaprevir might have a novel …
[Telaprevir-induced pityriasis rubra pilaris].
Schmutz JL, Trechot P. Schmutz JL, et al. Ann Dermatol Venereol. 2013 May;140(5):414-5. doi: 10.1016/j.annder.2013.01.336. Epub 2013 Mar 6. Ann Dermatol Venereol. 2013. PMID: 23663723 Review. French. No abstract available.
Telaprevir: pharmacokinetics and drug interactions.
Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. Garg V, et al. Antivir Ther. 2012;17(7):1211-21. doi: 10.3851/IMP2356. Epub 2012 Sep 7. Antivir Ther. 2012. PMID: 22954756 Review.
Telaprevir is extensively metabolized and primarily eliminated via faeces. ...This article reviews the pharmacokinetic and drug interaction profile of telaprevir....
Telaprevir is extensively metabolized and primarily eliminated via faeces. ...This article reviews the pharmacokinetic and drug inter …
1,575 results